BioLargo Inc (BLGO)
OTHER OTC:BLGO
BLGO Stock Chart & Stats
$0.19
<$0.01(0.17%)
At close: 4:00 PM EST
$0.19
<$0.01(0.17%)
Day’s Range― - ―
52-Week Range$0.14 - $0.29
Previous CloseN/A
Volume222.28K
Average Volume (3M)570.01K
Market Cap
$53.27M
Enterprise Value$52.96M
Total Cash (Recent Filing)$3.88M
Total Debt (Recent Filing)$3.51M
Price to Earnings (P/E)―
Beta-0.29
Next Earnings
May 20, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding319,750,850
10 Day Avg. Volume632,227
30 Day Avg. Volume570,010
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)14.00
Price to Sales (P/S)7.29
P/FCF Ratio-6.78
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue6.82
Enterprise Value/Gross Profit15.55
Enterprise Value/Ebitda-3.64
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$4.90M
Bulls Say, Bears Say
Bulls Say
Diversified Subsidiary Stakes & Royalty ModelBioLargo’s structure of owning significant equity in multiple operating platforms plus a 6% royalty creates a portfolio-style exposure to commercialization outcomes. This reduces single-product dependency, preserves upside from successful subsidiaries, and provides a recurring revenue/earnings channel as deployments scale.
Clyra FDA-cleared Commercial RolloutFDA 510(k) clearance plus an exclusive distribution agreement and initial paid orders materially de-risks market entry for Clyra. The commercial launch backed by recent capital infusion supports sustainable medical sales and potential repeat consumable demand, giving durable revenue growth potential if adoption continues.
AEC PFAS Field Validation With EPA MonitoringA municipal deployment under a formal EPA/NJDEP monitoring program represents regulatory validation for the AEC PFAS solution. Successful validation can unlock larger municipal and industrial procurement pipelines given rising regulatory mandates on PFAS, creating a multi‑year structural market opportunity for the technology.
Bears Say
Persistent Negative Cash GenerationConsistent negative operating and free cash flow indicates the business consumes capital rather than generates it, raising reliance on external financing or dilutive equity. Accelerated cash burn in 2025 limits runway for commercialization investments and increases execution risk for planned 2026 rollouts without new funding.
Revenue Decline And Widening Losses In 2025A sharp 2025 revenue drop alongside a materially wider net loss highlights fragile top‑line stability and a cost base that isn’t scaling efficiently. The deterioration reduced shareholder equity and shows that achieving sustainable profitability will require durable revenue recovery or meaningful structural cost changes.
Partner/license Termination And Credit LossLoss of a licensed partner and a booked credit loss materially reduced revenue and reveals partner concentration and contract execution risk. Ongoing litigation and recovery uncertainty impair near-term cash predictability and complicate converting pilot/partner wins into dependable, long‑term revenue streams.
BioLargo News
BLGO FAQ
What was BioLargo Inc’s price range in the past 12 months?
BioLargo Inc lowest stock price was $0.14 and its highest was $0.29 in the past 12 months.
What is BioLargo Inc’s market cap?
BioLargo Inc’s market cap is $53.27M.
When is BioLargo Inc’s upcoming earnings report date?
BioLargo Inc’s upcoming earnings report date is May 20, 2026 which is in 56 days.
How were BioLargo Inc’s earnings last quarter?
BioLargo Inc released its earnings results on Mar 05, 2026. The company reported -$0.012 earnings per share for the quarter, missing the consensus estimate of -$0.01 by -$0.002.
Is BioLargo Inc overvalued?
According to Wall Street analysts BioLargo Inc’s price is currently Overvalued.
Does BioLargo Inc pay dividends?
BioLargo Inc does not currently pay dividends.
What is BioLargo Inc’s EPS estimate?
BioLargo Inc’s EPS estimate is -0.01.
How many shares outstanding does BioLargo Inc have?
BioLargo Inc has 319,750,850 shares outstanding.
What happened to BioLargo Inc’s price movement after its last earnings report?
BioLargo Inc reported an EPS of -$0.012 in its last earnings report, missing expectations of -$0.01. Following the earnings report the stock price went down -5.587%.
Which hedge fund is a major shareholder of BioLargo Inc?
Currently, no hedge funds are holding shares in BLGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioLargo Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.75%
12-Months-Change
Fundamentals
Return on Equity
-174.59%
Trailing 12-Months
Asset Growth
-20.95%
Trailing 12-Months
Company Description
BioLargo Inc
BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services. The company's products include Advanced Oxidation system, a water treatment device that generates a series of oxidative and energetic species of iodine and other molecules; Aqueous Electrostatic Concentrator, a water treatment system that removes per- and poly-fluoroalkyl substances from water; CupriDyne Clean industrial products, which reduce and eliminate tough odors and volatile organic compounds in various industrial settings; and advanced wound care products. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
BLGO Company Deck
BLGO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced notable commercialization and validation milestones (Clyra launch and clinical data, AEC municipal install with EPA monitoring, Cellinity MOUs and technology validation, service revenue doubling, and preserved cash) against material near-term financial challenges (2025 revenue decline to $7.8M, $15.2M net loss, a booked credit loss, Pooph license termination and litigation, and diminished shareholders' equity). Management emphasizes transition from development to commercialization and several near-term catalysts for 2026, but the significant 2025 financial deterioration and ongoing legal/partner risks temper the outlook.View all BLGO earnings summariesTechnical Analysis
Ownership Overview
12.89% Insiders
0.04% Other Institutional Investors
87.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---